As of 2026-03-18, the EV/EBITDA ratio of Rapt Therapeutics Inc (RAPT) is -15.24. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RAPT's latest enterprise value is 1,642.33 mil USD. RAPT's TTM EBITDA according to its financial statements is -107.73 mil USD. Dividing these 2 quantities gives us the above RAPT EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2026-03-02 | -15.24 |
| 2026-02-27 | -15.23 |
| 2026-02-26 | -15.23 |
| 2026-02-25 | -15.23 |
| 2026-02-24 | -15.22 |
| 2026-02-23 | -15.22 |
| 2026-02-20 | -15.22 |
| 2026-02-19 | -15.19 |
| 2026-02-18 | -15.17 |
| 2026-02-17 | -15.20 |
| 2026-02-13 | -15.16 |
| 2026-02-12 | -15.19 |
| 2026-02-11 | -15.16 |
| 2026-02-10 | -15.17 |
| 2026-02-09 | -15.18 |
| 2026-02-06 | -15.16 |
| 2026-02-05 | -15.15 |
| 2026-02-04 | -15.18 |
| 2026-02-03 | -15.17 |
| 2026-02-02 | -15.15 |
| 2026-01-30 | -15.15 |
| 2026-01-29 | -15.14 |
| 2026-01-28 | -15.15 |
| 2026-01-27 | -15.13 |
| 2026-01-26 | -15.14 |
| 2026-01-23 | -15.14 |
| 2026-01-22 | -15.14 |
| 2026-01-21 | -15.13 |
| 2026-01-20 | -15.12 |
| 2026-01-16 | -9.08 |
| 2026-01-15 | -8.30 |
| 2026-01-14 | -8.98 |
| 2026-01-13 | -8.80 |
| 2026-01-12 | -8.90 |
| 2026-01-09 | -8.69 |
| 2026-01-08 | -8.04 |
| 2026-01-07 | -8.36 |
| 2026-01-06 | -7.94 |
| 2026-01-05 | -7.66 |
| 2026-01-02 | -8.21 |
| 2025-12-31 | -8.75 |
| 2025-12-30 | -8.62 |
| 2025-12-29 | -9.28 |
| 2025-12-26 | -9.17 |
| 2025-12-24 | -9.28 |
| 2025-12-23 | -9.16 |
| 2025-12-22 | -9.45 |
| 2025-12-19 | -8.74 |
| 2025-12-18 | -8.80 |
| 2025-12-17 | -8.57 |